<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ichthyosis vulgaris</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ichthyosis vulgaris</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Ichthyosis vulgaris</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan D Irvine, MD, DSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer L Hand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3763553116"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Ichthyosis vulgaris (IV; MIM #146700) is the most common of the ichthyoses, a heterogeneous group of inherited disorders of keratinization characterized by generalized scaling of the skin of varying severity  (<a class="graphic graphic_picture graphicRef61258" href="/d/graphic/61258.html" rel="external">picture 1A</a>). IV is generally considered mildest in comparison with other ichthyosis types [<a href="#rid1">1</a>]. IV is caused by pathogenic variants in the filaggrin gene (<em>FLG</em>), encoding profilaggrin, which is a major component of the keratohyalin granules in the granular layer of the epidermis [<a href="#rid2">2</a>].</p><p>This topic will review the pathogenesis, clinical features, diagnosis, and management of IV. An overview of syndromic and nonsyndromic ichthyoses is presented separately  (<a class="graphic graphic_table graphicRef90509" href="/d/graphic/90509.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef90504" href="/d/graphic/90504.html" rel="external">table 2</a>). Other types of inherited ichthyoses are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/112583.html" rel="external">"Autosomal recessive congenital ichthyoses"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15472.html" rel="external">"X-linked ichthyosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/97333.html" rel="external">"Keratinopathic ichthyoses"</a>.)</p><p></p><p class="headingAnchor" id="H2986038674"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Ichthyosis vulgaris (IV) is relatively common. Its exact prevalence is unknown, but the best available estimates in British populations suggest a prevalence between 1 in 80 to 1 in 250 individuals [<a href="#rid3">3,4</a>]. The prevalence of identified <em>FLG </em>null variants in Europe varies from 2.7 to 14.2 percent, with a median of 7.7 percent and 83 to 96 percent penetrance [<a href="#rid5">5-9</a>]. Prevalence in other populations may be lower, ranging from 1 to 6.5 percent in Chinese and Japanese populations to 0.5 to 1.3 percent in African Americans [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H724880177"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H338281410"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>Ichthyosis vulgaris (IV) is caused by loss-of-function variants in the filaggrin gene (<em>FLG</em>) on chromosome 1q21.3, encoding the protein profilaggrin, which is a major component of the keratohyalin granules in the granular layer of the epidermis [<a href="#rid2">2</a>]. <em>FLG</em> variants result in impaired epidermal barrier function and reduced formation of the natural moisturizing factor.</p><p>The IV inheritance pattern is semidominant, with individuals inheriting a single mutated allele being much less severely affected than those with homozygous or compound heterozygous variants [<a href="#rid2">2</a>]. Although early studies supported the role of <em>FLG</em> variants in the pathogenesis of IV, the highly repetitive sequence of human <em>FLG</em> repeats with varying numbers of repeats (10 to 12) and limited heterogeneity between repeats thwarted initial efforts to sequence the gene [<a href="#rid10">10-12</a>]. Studies of large kindreds with the clinical and histologic phenotype of IV finally led to identification of loss-of-function variants in the first (amino-terminal) full FLG monomer and demonstrated the semidominant inheritance of IV [<a href="#rid2">2</a>]. <em>FLG</em> null variants show incomplete penetrance and variable expressivity within families [<a href="#rid2">2</a>]. These findings led to a sequencing strategy that allows sequencing of the entire third profilaggrin exon and recognition that both common and uncommon loss-of-function mutations exist [<a href="#rid5">5</a>].</p><p>In the Northern European population, approximately 80 percent of the loss-of-function variants are seen in the two alleles initially identified (R501X, arginine to stop codon; and 2282 del 4, deletion of a 4-bp segment in position 2282 of the <em>FLG</em> coding sequence). Both variants lead to premature stop codons in the first <em>FLG</em> repeat and lack of profilaggrin expression in the epidermis of affected individuals. However, many less common variants have been shown. Over 60 loss-of-function variants, with more described as studies continue, have been demonstrated, with many specific to other regions and populations [<a href="#rid6">6,13</a>]. Regardless of which of the 10 to 12 FLG repeats is affected, loss-of-function variants in <em>FLG </em>lead to almost total loss of keratohyalin granules and FLG expression and are associated with additional abnormalities in keratinization [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H3886503537"><span class="h2">Impairment of the skin barrier</span><span class="headingEndMark"> — </span>Barrier function of the epidermis is established through an elaborate series of pathways as epidermal cells (keratinocytes) differentiate and are ultimately desquamated [<a href="#rid15">15-17</a>]. A critical anatomic area in this process is the junction of the granular and cornified cell layers, where keratohyalin granules disappear; lamellar bodies secrete their contents into the intercellular space; nuclei and cytoplasmic contents are degraded; keratin intermediate filaments aggregate; and the keratinocyte plasma membrane is replaced by a chemically resistant, cornified envelope in which lipids, desmosomal proteins, and other peptides are covalently crosslinked. As cells in the cornified layer flatten, keratin filaments condense and are covalently crosslinked within the cornified envelope to form squamous cells.</p><p>Filaggrin (FLG) is named for its participation in keratin filament aggregation and plays an important role in the formation of the epidermal barrier [<a href="#rid16">16,18</a>]. FLG is synthesized in the granular layer as a large, approximately 400 kb precursor profilaggrin that is highly phosphorylated post-translationally, which may account for its precipitation into intracellular granules; profilaggrin makes up most of the content of keratohyalin granules in human interfollicular skin. Profilaggrin is a member of the S-100-fused, calcium-binding proteins [<a href="#rid19">19</a>]. Genes coding for several of the S-100 proteins are located on chromosome 1 in the epidermal differentiation complex, along with those that code for other precursors of the cornified envelope and other proteins involved in epidermal differentiation [<a href="#rid20">20</a>]. </p><p><em>FLG</em> contains three exons; the third exon codes for most of an amino-terminal segment, a partial FLG repeat, 10 to 12 FLG repeat monomers of identical 972 base pair length, a second partial FLG repeat, and a short carboxy-terminal segment. FLG repeats are connected by short linker peptides, much like beads on a string [<a href="#rid21">21,22</a>]. Profilaggrin does not participate in aggregation of keratin filaments. At the granular-stratum corneum interface, profilaggrin is rapidly dephosphorylated and proteolyzed to FLG monomers, which are thought to aggregate and condense keratin filaments [<a href="#rid23">23</a>]. Aggregated keratin filaments are covalently crosslinked and serve as a scaffold for formation of the cornified envelope.</p><p>Portions of FLG remain covalently bound to the cornified envelope, but most of the protein is proteolyzed to component residues that contribute to hydration of the upper layers of the cornified layer and, possibly, pH control, ultraviolet (UV) protection, and immune function [<a href="#rid24">24</a>]. Postulated roles for the amino- and carboxy-terminal segments are beyond the scope of this topic; however the carboxy-terminal segment appears to be necessary for the processing of profilaggrin to monomers [<a href="#rid5">5</a>]. This may explain the almost complete loss of FLG expression in loss-of-function mutations, regardless of which of the 10 to 12 repeats is affected.</p><p class="headingAnchor" id="H1818767166"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H4222606332"><span class="h2">Cutaneous findings</span><span class="headingEndMark"> — </span>Ichthyosis vulgaris (IV) presents in infancy or early childhood as diffuse, scaly skin with centrally attached, fine, white or light-gray scale  (<a class="graphic graphic_picture graphicRef122050" href="/d/graphic/122050.html" rel="external">picture 1D</a>). Extensor extremities and the trunk are commonly affected, with sparing of intertriginous (eg, axillary, antecubital, popliteal) skin  (<a class="graphic graphic_picture graphicRef61258 graphicRef79894 graphicRef68882" href="/d/graphic/61258.html" rel="external">picture 1A-C</a>). Involvement of the sides of the neck is uncommon. The severity of scaling is variable. Individuals with one mutated allele (heterozygotes) have a mild phenotype that can be confused with simple dry skin, whereas those with mutations in both alleles (homozygous or compound heterozygotes) have more apparent disease. There is a marked seasonal variation in severity, with improvement in warm and sunny weather with high degree of ambient humidity and worsening in dry and cold environment. </p><p>Increased major and minor lines (hyperlinearity) of the palms are commonly seen  (<a class="graphic graphic_picture graphicRef90481" href="/d/graphic/90481.html" rel="external">picture 2A</a>), along with keratosis pilaris  (<a class="graphic graphic_picture graphicRef60786 graphicRef68488" href="/d/graphic/60786.html" rel="external">picture 3A-B</a>). (See  <a class="medical medical_review" href="/d/html/13663.html" rel="external">"Keratosis pilaris"</a>.)</p><p>Hyperlinearity of the thenar eminence is thought to be more specific to IV  (<a class="graphic graphic_picture graphicRef122051" href="/d/graphic/122051.html" rel="external">picture 2B</a>) [<a href="#rid25">25</a>]. Although both of these findings are not restricted to IV, palmar hyperlinearity is reported in 34 to 71 percent of those with common null variants (positive predictive value), while 85.5 to 90 percent of those without palmar hyperlinearity do not carry identified variants (negative predictive value). For keratosis pilaris, the positive and negative predictive value are 32 to 53 percent and 79 to 90 percent, respectively [<a href="#rid3">3,26</a>]. </p><p class="headingAnchor" id="H2832397675"><span class="h2">Other physical findings</span><span class="headingEndMark"> — </span>Corneal biomechanical properties (eg, corneal resistance factor, central corneal thickness, and intraocular pressure) are lower in IV, which could result in false negatives when screening for glaucoma and should be considered in patients with IV undergoing refractive surgery [<a href="#rid27">27</a>]. Heat intolerance is reported by some affected individuals, although whether this is related to IV or associated atopic eczema is unclear [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H3421814195"><span class="h1">ASSOCIATED CONDITIONS</span></p><p class="headingAnchor" id="H2289228556"><span class="h2">Atopic dermatitis and other atopic diseases</span><span class="headingEndMark"> — </span>A strong association of atopic dermatitis with ichthyosis vulgaris (IV) was noted soon after null variants of the filaggrin gene (<em>FLG</em>) were identified in patients with atopic eczema [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p>Over 20 studies have confirmed this association, which is one of the most robust gene associations thus far identified in complex trait genetics [<a href="#rid28">28-31</a>]. <em>FLG </em>variants are associated with early-onset, moderate to severe, persistent eczema; asthma in the setting of eczema; and allergic rhinitis [<a href="#rid32">32-34</a>]. However, penetrance is not complete, with only 37 to 70 percent of individuals with the clinical diagnosis of IV having atopic conditions or a peanut allergy [<a href="#rid4">4,25,35,36</a>].</p><p class="headingAnchor" id="H3281666934"><span class="h2">Other skin disease</span><span class="headingEndMark"> — </span>Mutations in <em>FLG</em> have been associated with a more severe phenotype of X-linked ichthyosis and possibly with pachyonychia congenita, and chondrodysplasia punctata type II [<a href="#rid37">37-41</a>]. (See  <a class="medical medical_review" href="/d/html/15472.html" rel="external">"X-linked ichthyosis"</a> and  <a class="medical medical_review" href="/d/html/15504.html" rel="external">"Pachyonychia congenita"</a> and  <a class="medical medical_review" href="/d/html/108252.html" rel="external">"Skeletal dysplasias: Specific disorders", section on 'Chondrodysplasia punctata'</a>.)</p><p>No association has been reported with other more common skin disorders, such as acne or psoriasis, or other inflammatory diseases, such as inflammatory bowel disease or sarcoidosis [<a href="#rid42">42-45</a>].</p><p class="headingAnchor" id="H1683550055"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>In homozygotes and compound heterozygotes for filaggrin gene (<em>FLG</em>) variants, histology shows orthohyperkeratosis, with a granular layer severely diminished or absent  (<a class="graphic graphic_picture graphicRef122057" href="/d/graphic/122057.html" rel="external">picture 4</a>). This is accompanied by virtual absence of immunoreactivity to antibodies to FLG  (<a class="graphic graphic_picture graphicRef122264" href="/d/graphic/122264.html" rel="external">picture 5</a>) [<a href="#rid2">2</a>]. Absent or "crumbly" keratohyalin granules are seen on electron microscopy  (<a class="graphic graphic_picture graphicRef122056" href="/d/graphic/122056.html" rel="external">picture 6</a>) [<a href="#rid2">2,46,47</a>]. Histologic findings in heterozygotes are variable.</p><p class="headingAnchor" id="H2786981367"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H834274652"><span class="h2">Clinical</span><span class="headingEndMark"> — </span>The clinical diagnosis of ichthyosis vulgaris (IV) is based on the combination of clinical findings on physical examination and the patient's personal and family history. Although the clinical diagnosis may be relatively easy in patients carrying homozygous or compound heterozygous variants of the filaggrin gene (<em>FLG</em>) who have a more severe phenotype, it may be elusive in heterozygotes, who typically have a very mild phenotype.</p><p>Clinical findings that suggest the diagnosis of IV include:</p><p class="bulletIndent1"><span class="glyph">●</span>Scale – Fine, white or gray, central attachment; involvement of extensor surface of extremities and trunk; sparing of folds  (<a class="graphic graphic_picture graphicRef122050 graphicRef61258 graphicRef79894 graphicRef68882" href="/d/graphic/122050.html" rel="external">picture 1A-D</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Palmar hyperlinearity – Accentuated major fissures, increased minor fissures; accentuated lines on thenar eminence  (<a class="graphic graphic_picture graphicRef90481 graphicRef122051" href="/d/graphic/90481.html" rel="external">picture 2A-B</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Keratosis pilaris  (<a class="graphic graphic_picture graphicRef60786 graphicRef68488" href="/d/graphic/60786.html" rel="external">picture 3A-B</a>).</p><p></p><p>Elements of personal and family history that support the diagnosis of IV include:</p><p class="bulletIndent1"><span class="glyph">●</span>Onset after birth, often in early childhood</p><p class="bulletIndent1"><span class="glyph">●</span>Improvement with warm weather and emollients</p><p class="bulletIndent1"><span class="glyph">●</span>Possible improvement with age</p><p class="bulletIndent1"><span class="glyph">●</span>Association with atopic eczema or other atopic diseases</p><p class="bulletIndent1"><span class="glyph">●</span>Familial occurrence </p><p></p><p class="headingAnchor" id="H1535768007"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>A skin biopsy is usually not necessary for the diagnosis. If performed, hematoxylin and eosin staining showing marked reduction or absence of the granular layer in the epidermis  (<a class="graphic graphic_picture graphicRef122057" href="/d/graphic/122057.html" rel="external">picture 4</a>) confirms the diagnosis of IV (see <a class="local">'Pathology'</a> above). The extensor aspect of the arm or shin are ideal sites for biopsy. Electron microscopy, although rarely used for routine skin diagnosis, may confirm keratohyalin granule abnormalities.</p><p class="headingAnchor" id="H1875419329"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>Genetic testing demonstrating pathogenic variants in the <em>FLG</em> gene provides the definitive diagnosis of IV, although this is not routinely done in clinical practice. The difficulty in sequencing the gene and heterogeneity among populations makes the molecular diagnosis difficult and, undoubtedly, results in underestimation of both variant prevalence and disorders associated with <em>FLG</em> variants. Adding to the difficulty in clinical diagnosis is the very mild phenotype seen in heterozygotes.</p><p>Common population associations may be useful for screening, although variants vary among populations, and identification of "private" variants is difficult and may be missed, unless Sanger sequencing or an equivalently comprehensive analysis of the entire gene is conducted.</p><p>In the United States, Clinical Laboratory Improvement Amendments (CLIA)-certified genetic testing is available from multiple commercial laboratories. Information on CLIA-certified and research-based laboratories performing disease-specific genetic testing worldwide is available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=15471" target="_blank">Genetic Testing Registry</a>.</p><p class="headingAnchor" id="H1642694777"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recessive X-linked ichthyosis</strong> – Recessive X-linked ichthyosis (XLI, MIM #308100) is the second most common ichthyosis after ichthyosis vulgaris (IV); it is caused by deletions or mutations in the <em>STS</em> gene encoding the steroid sulfatase enzyme [<a href="#rid48">48</a>]. It presents in the first few weeks of life with mild, diffuse scaling  (<a class="graphic graphic_picture graphicRef103929" href="/d/graphic/103929.html" rel="external">picture 7</a>). Over time, large, polygonal scales may become apparent, especially on the anterior aspect of the lower legs  (<a class="graphic graphic_picture graphicRef122236" href="/d/graphic/122236.html" rel="external">picture 8</a>). During childhood, the scalp, preauricular areas, and neck may be involved. Palmar hyperlinearity is generally absent in XLI. The diagnosis of recessive XLI can be supported by fluorescence in situ hybridization studies, as approximately 90 percent of affected individuals have detectable abnormalities. The diagnosis can be confirmed by demonstrating reduced steroid sulfatase activity in cultured fibroblasts from a skin biopsy, by reduced serum levels of steroid sulfatase, or by genetic testing. (See  <a class="medical medical_review" href="/d/html/15472.html" rel="external">"X-linked ichthyosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dry skin</strong> – Dry skin and desquamation is a common feature of atopic dermatitis. It is generally less severe than IV. Palmar hyperlinearity is less common, as is keratosis pilaris. (See  <a class="medical medical_review" href="/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acquired ichthyosis </strong>–<strong> </strong>Acquired ichthyosis is clinically and histologically similar to IV  (<a class="graphic graphic_picture graphicRef57819" href="/d/graphic/57819.html" rel="external">picture 9</a>). In contrast with the inherited IV, it develops later in life and is usually associated with malignancy, most frequently Hodgkin lymphoma and other lymphoproliferative disorders, or systemic diseases [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/d/html/7606.html" rel="external">"Cutaneous manifestations of internal malignancy", section on 'Acquired ichthyosis'</a>.)</p><p></p><p class="headingAnchor" id="H84123774"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The treatment of ichthyosis vulgaris (IV) is directed at removing scales, reducing skin dryness, and improving skin appearance. It involves regular bathing and use of moisturizers and keratolytics. An overview of the management of the inherited ichthyoses is provided separately. (See  <a class="medical medical_review" href="/d/html/128456.html" rel="external">"Inherited ichthyosis: Overview of management"</a>.)</p><p class="headingAnchor" id="H420146885"><span class="h2">Bathing</span><span class="headingEndMark"> — </span>Individuals with dry skin, including those with IV, are often encouraged to take long baths to facilitate scale removal. This advice makes common sense and has withstood the test of time, although limited studies support it [<a href="#rid50">50</a>]. The benefit of bath additives, including oils and <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a>, is controversial [<a href="#rid51">51</a>]. Bathing with or without the use of soaps or synthetic detergents should be followed by the application of moisturizers.</p><p class="headingAnchor" id="H3110539710"><span class="h2">Emollients and moisturizers</span><span class="headingEndMark"> — </span>Frequent and liberal use of emollients and moisturizers is the mainstay of treatment for IV [<a href="#rid52">52</a>]. Moisturizers hydrate and smooth the skin. Components include humectants, such as <a class="drug drug_general" data-topicid="8959" href="/d/drug information/8959.html" rel="external">glycerin</a>; occlusives, such as petrolatum; emollients, such as cetyl alcohol; keratolytics, such as urea and alpha-hydroxy acids; and other components. Humectants draw and hold water in the epidermis; occlusives prevent water loss; emollients, which are water insoluble but of lower molecular weight than occlusives, smooth the skin; and keratolytics aid in removing scale [<a href="#rid53">53</a>].</p><p>The choice of moisturizers for the treatment of IV is generally based on patient preference and personal experience. Studies comparing different moisturizers for IV are limited and generally of low quality [<a href="#rid54">54</a>].</p><p>A few studies suggest that keratolytics, such as urea, alpha-hydroxy acids, and salicylic acid, are superior to simple emollients [<a href="#rid55">55-57</a>]. In a systematic review of 48 randomized trials and uncontrolled studies including 3262 patients with atopic eczema or IV, moisturizers (and especially those containing urea or <a class="drug drug_general" data-topicid="8959" href="/d/drug information/8959.html" rel="external">glycerin</a>) were generally beneficial in improving the clinical symptoms of atopic dermatitis and IV [<a href="#rid54">54</a>]. Studies comparing the efficacy of different moisturizers for IV are lacking. A meta-analysis of 77 randomized trials assessing the efficacy of different moisturizers for atopic dermatitis, while demonstrating a beneficial effect for most moisturizers, did not find evidence that one moisturizer is superior to another [<a href="#rid58">58</a>].</p><p>Topical retinoids, topical corticosteroids, calcipotriene, and systemic retinoids are <strong>not</strong> indicated in the treatment of IV. The treatment of associated atopic dermatitis is discussed elsewhere [<a href="#rid50">50,51</a>]. (See  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)"</a>.)</p><p class="headingAnchor" id="H3981089045"><span class="h1">PROGNOSIS AND FOLLOW-UP</span><span class="headingEndMark"> — </span>Individuals with ichthyosis vulgaris (IV) live normal lives with no known compromise to longevity but must deal with daily treatment of scaling skin disease, often in the context of moderate to severe atopic eczema. Quality-of-life studies in the ichthyoses focus on the more severe disorders [<a href="#rid59">59</a>]; none has addressed IV. </p><p>Most individuals with ichthyosis desire information about their disorder and how to treat it most effectively. Once they have this information, they usually have better insight into what works for their skin and rarely seek care unless problems are encountered. This applies more so to IV, where the most issues with treatment and complications are associated with eczema. </p><p class="headingAnchor" id="H2596653474"><span class="h1">SUPPORT GROUPS</span><span class="headingEndMark"> — </span>The Foundation for Ichthyosis and Related Skin Types (FIRST) is a lay organization that supports affected individuals, their family members, and professionals. Information about the ichthyoses and associated support groups, research studies, and therapeutic help is available online at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.firstskinfoundation.org%2F&amp;token=oN6rXOmeBLkIpfIsq5mH5Z0Le%2Fvc5VRvejbPvZqw%2FIYldSRDD4QEGzmgJ%2BviBi8p&amp;TOPIC_ID=15471" target="_blank">FIRST</a>.</p><p class="headingAnchor" id="H3749744492"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/129484.html" rel="external">"Society guideline links: Ichthyosis"</a>.)</p><p class="headingAnchor" id="H3089408650"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Ichthyosis vulgaris (IV) is the most common of the inherited ichthyoses, a heterogeneous group of disorders of keratinization characterized by generalized scaling of the skin of varying severity and impairment of the skin barrier function. IV is caused by loss-of-function variants in the <em>FLG</em> gene, encoding the protein profilaggrin, a major component of the keratohyalin granules in the granular layer of the epidermis. (See <a class="local">'Pathogenesis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – IV presents in infancy or early childhood as diffuse, scaly skin with centrally attached, fine, white or light-gray scale  (<a class="graphic graphic_picture graphicRef122050" href="/d/graphic/122050.html" rel="external">picture 1D</a>). Extensor extremities and the trunk are commonly affected, with sparing of intertriginous (eg, axillary, antecubital, popliteal) skin  (<a class="graphic graphic_picture graphicRef61258 graphicRef79894 graphicRef68882" href="/d/graphic/61258.html" rel="external">picture 1A-C</a>). Palmar hyperlinearity is characteristic  (<a class="graphic graphic_picture graphicRef90481" href="/d/graphic/90481.html" rel="external">picture 2A</a>). Atopic dermatitis is frequently associated in affected individuals. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of IV is suspected in individuals presenting with diffuse scaling of the skin since childhood, palmar hyperlinearity, and a positive family history of the disease. A skin biopsy for hematoxylin and eosin staining showing severe reduction or absence of the granular layer  (<a class="graphic graphic_picture graphicRef122057" href="/d/graphic/122057.html" rel="external">picture 4</a>) may be helpful to confirm the diagnosis. Genetic testing demonstrating pathogenic variants in the <em>FLG</em> gene provides the definitive diagnosis, although this is not routinely done in clinical practice. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The treatment of IV is directed at removing scales, reducing skin dryness, and improving skin appearance. It involves regular bathing and frequent and liberal use of moisturizers and keratolytics. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/d/html/128456.html" rel="external">"Inherited ichthyosis: Overview of management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Support groups</strong> – Information about the ichthyoses and associated support groups, research studies, and therapeutic help is available at the Foundation for Ichthyosis and Related Skin Types (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.firstskinfoundation.org%2F&amp;token=oN6rXOmeBLkIpfIsq5mH5Z0Le%2Fvc5VRvejbPvZqw%2FIYldSRDD4QEGzmgJ%2BviBi8p&amp;TOPIC_ID=15471" target="_blank">FIRST</a>), a lay organization that supports affected individuals, their family members, and professionals. (See <a class="local">'Support groups'</a> above.)</p><p></p><p class="headingAnchor" id="H3138213804"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Philip Fleckman, MD (deceased), who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Oji V, Tadini G, Akiyama M, et al. Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Sorèze 2009. J Am Acad Dermatol 2010; 63:607.</a></li><li><a class="nounderline abstract_t">Smith FJ, Irvine AD, Terron-Kwiatkowski A, et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet 2006; 38:337.</a></li><li><a class="nounderline abstract_t">Brown SJ, Relton CL, Liao H, et al. Filaggrin null mutations and childhood atopic eczema: a population-based case-control study. J Allergy Clin Immunol 2008; 121:940.</a></li><li><a class="nounderline abstract_t">Wells RS, Kerr CB. Clinical features of autosomal dominant and sex-linked ichthyosis in an English population. Br Med J 1966; 1:947.</a></li><li><a class="nounderline abstract_t">Sandilands A, Terron-Kwiatkowski A, Hull PR, et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet 2007; 39:650.</a></li><li><a class="nounderline abstract_t">Thyssen JP, Godoy-Gijon E, Elias PM. Ichthyosis vulgaris: the filaggrin mutation disease. Br J Dermatol 2013; 168:1155.</a></li><li><a class="nounderline abstract_t">Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38:441.</a></li><li><a class="nounderline abstract_t">Oji V, Seller N, Sandilands A, et al. Ichthyosis vulgaris: novel FLG mutations in the German population and high presence of CD1a+ cells in the epidermis of the atopic subgroup. Br J Dermatol 2009; 160:771.</a></li><li><a class="nounderline abstract_t">Gruber R, Janecke AR, Fauth C, et al. Filaggrin mutations p.R501X and c.2282del4 in ichthyosis vulgaris. Eur J Hum Genet 2007; 15:179.</a></li><li><a class="nounderline abstract_t">Sybert VP, Dale BA, Holbrook KA. Ichthyosis vulgaris: identification of a defect in synthesis of filaggrin correlated with an absence of keratohyaline granules. J Invest Dermatol 1985; 84:191.</a></li><li><a class="nounderline abstract_t">Nirunsuksiri W, Zhang SH, Fleckman P. Reduced stability and bi-allelic, coequal expression of profilaggrin mRNA in keratinocytes cultured from subjects with ichthyosis vulgaris. J Invest Dermatol 1998; 110:854.</a></li><li><a class="nounderline abstract_t">Compton JG, DiGiovanna JJ, Johnston KA, et al. Mapping of the associated phenotype of an absent granular layer in ichthyosis vulgaris to the epidermal differentiation complex on chromosome 1. Exp Dermatol 2002; 11:518.</a></li><li><a class="nounderline abstract_t">Li M, Liu Q, Liu J, et al. Mutations analysis in filaggrin gene in northern China patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2013; 27:169.</a></li><li><a class="nounderline abstract_t">Gruber R, Elias PM, Crumrine D, et al. Filaggrin genotype in ichthyosis vulgaris predicts abnormalities in epidermal structure and function. Am J Pathol 2011; 178:2252.</a></li><li><a class="nounderline abstract_t">Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol 2005; 6:328.</a></li><li><a class="nounderline abstract_t">Sandilands A, Sutherland C, Irvine AD, McLean WH. Filaggrin in the frontline: role in skin barrier function and disease. J Cell Sci 2009; 122:1285.</a></li><li><a class="nounderline abstract_t">Natsuga K. Epidermal barriers. Cold Spring Harb Perspect Med 2014; 4:a018218.</a></li><li><a class="nounderline abstract_t">Steinert PM, Cantieri JS, Teller DC, et al. Characterization of a class of cationic proteins that specifically interact with intermediate filaments. Proc Natl Acad Sci U S A 1981; 78:4097.</a></li><li><a class="nounderline abstract_t">Wu Z, Hansmann B, Meyer-Hoffert U, et al. Molecular identification and expression analysis of filaggrin-2, a member of the S100 fused-type protein family. PLoS One 2009; 4:e5227.</a></li><li><a class="nounderline abstract_t">Segre JA. Epidermal differentiation complex yields a secret: mutations in the cornification protein filaggrin underlie ichthyosis vulgaris. J Invest Dermatol 2006; 126:1202.</a></li><li><a class="nounderline abstract_t">Presland RB, Haydock PV, Fleckman P, et al. Characterization of the human epidermal profilaggrin gene. Genomic organization and identification of an S-100-like calcium binding domain at the amino terminus. J Biol Chem 1992; 267:23772.</a></li><li><a class="nounderline abstract_t">Markova NG, Marekov LN, Chipev CC, et al. Profilaggrin is a major epidermal calcium-binding protein. Mol Cell Biol 1993; 13:613.</a></li><li><a class="nounderline abstract_t">Dale BA, Holbrook KA, Steinert PM. Assembly of stratum corneum basic protein and keratin filaments in macrofibrils. Nature 1978; 276:729.</a></li><li><a class="nounderline abstract_t">Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med 2011; 365:1315.</a></li><li><a class="nounderline abstract_t">Brown SJ, Relton CL, Liao H, et al. Filaggrin haploinsufficiency is highly penetrant and is associated with increased severity of eczema: further delineation of the skin phenotype in a prospective epidemiological study of 792 school children. Br J Dermatol 2009; 161:884.</a></li><li><a class="nounderline abstract_t">Chen H, Common JE, Haines RL, et al. Wide spectrum of filaggrin-null mutations in atopic dermatitis highlights differences between Singaporean Chinese and European populations. Br J Dermatol 2011; 165:106.</a></li><li><a class="nounderline abstract_t">Kara N, Yildirim Y, Demircan A, et al. Topographic and biomechanical evaluation of cornea in patients with ichthyosis vulgaris. Cont Lens Anterior Eye 2012; 35:208.</a></li><li><a class="nounderline abstract_t">Brown SJ, McLean WH. One remarkable molecule: filaggrin. J Invest Dermatol 2012; 132:751.</a></li><li><a class="nounderline abstract_t">Rodríguez E, Baurecht H, Herberich E, et al. Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease. J Allergy Clin Immunol 2009; 123:1361.</a></li><li><a class="nounderline abstract_t">van den Oord RA, Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. BMJ 2009; 339:b2433.</a></li><li><a class="nounderline abstract_t">O'Regan GM, Sandilands A, McLean WHI, Irvine AD. Filaggrin in atopic dermatitis. J Allergy Clin Immunol 2008; 122:689.</a></li><li><a class="nounderline abstract_t">Brown SJ, Sandilands A, Zhao Y, et al. Prevalent and low-frequency null mutations in the filaggrin gene are associated with early-onset and persistent atopic eczema. J Invest Dermatol 2008; 128:1591.</a></li><li><a class="nounderline abstract_t">Weidinger S, O'Sullivan M, Illig T, et al. Filaggrin mutations, atopic eczema, hay fever, and asthma in children. J Allergy Clin Immunol 2008; 121:1203.</a></li><li><a class="nounderline abstract_t">Gao PS, Rafaels NM, Hand T, et al. Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum. J Allergy Clin Immunol 2009; 124:507.</a></li><li><a class="nounderline abstract_t">Bremmer SF, Hanifin JM, Simpson EL. Clinical detection of ichthyosis vulgaris in an atopic dermatitis clinic: implications for allergic respiratory disease and prognosis. J Am Acad Dermatol 2008; 59:72.</a></li><li><a class="nounderline abstract_t">Brown SJ, Asai Y, Cordell HJ, et al. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J Allergy Clin Immunol 2011; 127:661.</a></li><li><a class="nounderline abstract_t">Liao H, Waters AJ, Goudie DR, et al. Filaggrin mutations are genetic modifying factors exacerbating X-linked ichthyosis. J Invest Dermatol 2007; 127:2795.</a></li><li><a class="nounderline abstract_t">Ramesh R, Chen H, Kukula A, et al. Exacerbation of X-linked ichthyosis phenotype in a female by inheritance of filaggrin and steroid sulfatase mutations. J Dermatol Sci 2011; 64:159.</a></li><li><a class="nounderline abstract_t">Wang X, Tan L, Shen N, et al. Exacerbation of ichthyosis vulgaris phenotype by co-inheritance of STS and FLG mutations in a Chinese family with ichthyosis: a case report. BMC Med Genet 2018; 19:120.</a></li><li><a class="nounderline abstract_t">Gruber R, Wilson NJ, Smith FJ, et al. Increased pachyonychia congenita severity in patients with concurrent keratin and filaggrin mutations. Br J Dermatol 2009; 161:1391.</a></li><li><a class="nounderline abstract_t">Jeong HS, Funari T, Gordon K, et al. Concurrent Chondrodysplasia Punctata Type 2 (Conradi-Hunermann-Happle Syndrome) and Ichthyosis Vulgaris in Teenaged Twin Girls. Pediatr Dermatol 2017; 34:e245.</a></li><li><a class="nounderline abstract_t">Common JE, Brown SJ, Haines RL, et al. Filaggrin null mutations are not a protective factor for acne vulgaris. J Invest Dermatol 2011; 131:1378.</a></li><li><a class="nounderline abstract_t">Zhao Y, Terron-Kwiatkowski A, Liao H, et al. Filaggrin null alleles are not associated with psoriasis. J Invest Dermatol 2007; 127:1878.</a></li><li><a class="nounderline abstract_t">Ruether A, Stoll M, Schwarz T, et al. Filaggrin loss-of-function variant contributes to atopic dermatitis risk in the population of Northern Germany. Br J Dermatol 2006; 155:1093.</a></li><li><a class="nounderline abstract_t">Van Limbergen J, Russell RK, Nimmo ER, et al. Filaggrin loss-of-function variants are associated with atopic comorbidity in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2009; 15:1492.</a></li><li><a class="nounderline abstract_t">Anton-Lamprecht I, Hofbauer M. Ultrastructural distinction of autosomal dominant ichthyosis vulgaris and X-linked recessive ichthyosis. Humangenetik 1972; 15:261.</a></li><li><a class="nounderline abstract_t">Fleckman P, Brumbaugh S. Absence of the granular layer and keratohyalin define a morphologically distinct subset of individuals with ichthyosis vulgaris. Exp Dermatol 2002; 11:327.</a></li><li><a class="nounderline abstract_t">Fernandes NF, Janniger CK, Schwartz RA. X-linked ichthyosis: an oculocutaneous genodermatosis. J Am Acad Dermatol 2010; 62:480.</a></li><li><a class="nounderline abstract_t">Patel N, Spencer LA, English JC 3rd, Zirwas MJ. Acquired ichthyosis. J Am Acad Dermatol 2006; 55:647.</a></li><li><a class="nounderline abstract_t">Gittler JK, Wang JF, Orlow SJ. Bathing and Associated Treatments in Atopic Dermatitis. Am J Clin Dermatol 2017; 18:45.</a></li><li><a class="nounderline abstract_t">Milstone LM. Scaly skin and bath pH: rediscovering baking soda. J Am Acad Dermatol 2010; 62:885.</a></li><li><a class="nounderline abstract_t">Mazereeuw-Hautier J, Vahlquist A, Traupe H, et al. Management of congenital ichthyoses: European guidelines of care, part one. Br J Dermatol 2019; 180:272.</a></li><li><a class="nounderline abstract_t">Lee C, Bajor J, Moaddel T, et al. Principles of Moisturizer Product Design. J Drugs Dermatol 2019; 18:s89.</a></li><li><a class="nounderline abstract_t">Lindh JD, Bradley M. Clinical Effectiveness of Moisturizers in Atopic Dermatitis and Related Disorders: A Systematic Review. Am J Clin Dermatol 2015; 16:341.</a></li><li><a class="nounderline abstract_t">Buxman M, Hickman J, Ragsdale W, et al. Therapeutic activity of lactate 12% lotion in the treatment of ichthyosis. Active versus vehicle and active versus a petrolatum cream. J Am Acad Dermatol 1986; 15:1253.</a></li><li><a class="nounderline abstract_t">Tadini G, Giustini S, Milani M. Efficacy of topical 10% urea-based lotion in patients with ichthyosis vulgaris: a two-center, randomized, controlled, single-blind, right-vs.-left study in comparison with standard glycerol-based emollient cream. Curr Med Res Opin 2011; 27:2279.</a></li><li><a class="nounderline abstract_t">Celleno L. Topical urea in skincare: A review. Dermatol Ther 2018; 31:e12690.</a></li><li><a class="nounderline abstract_t">van Zuuren EJ, Fedorowicz Z, Arents BWM. Emollients and moisturizers for eczema: abridged Cochrane systematic review including GRADE assessments. Br J Dermatol 2017; 177:1256.</a></li><li><a class="nounderline abstract_t">Dreyfus I, Pauwels C, Bourrat E, et al. Burden of inherited ichthyosis: a French national survey. Acta Derm Venereol 2015; 95:326.</a></li></ol></div><div id="topicVersionRevision">Topic 15471 Version 6.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20643494" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Sorèze 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16444271" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18313126" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Filaggrin null mutations and childhood atopic eczema: a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20790920" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical features of autosomal dominant and sex-linked ichthyosis in an English population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17417636" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23301728" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Ichthyosis vulgaris: the filaggrin mutation disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16550169" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19183181" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Ichthyosis vulgaris: novel FLG mutations in the German population and high presence of CD1a+ cells in the epidermis of the atopic subgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17164798" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Filaggrin mutations p.R501X and c.2282del4 in ichthyosis vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2579164" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Ichthyosis vulgaris: identification of a defect in synthesis of filaggrin correlated with an absence of keratohyaline granules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9620289" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Reduced stability and bi-allelic, coequal expression of profilaggrin mRNA in keratinocytes cultured from subjects with ichthyosis vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12473059" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mapping of the associated phenotype of an absent granular layer in ichthyosis vulgaris to the epidermal differentiation complex on chromosome 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22220561" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mutations analysis in filaggrin gene in northern China patients with atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21514438" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Filaggrin genotype in ichthyosis vulgaris predicts abnormalities in epidermal structure and function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15803139" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The cornified envelope: a model of cell death in the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19386895" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Filaggrin in the frontline: role in skin barrier function and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24692192" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Epidermal barriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6170061" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Characterization of a class of cationic proteins that specifically interact with intermediate filaments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384417" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Molecular identification and expression analysis of filaggrin-2, a member of the S100 fused-type protein family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16702965" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Epidermal differentiation complex yields a secret: mutations in the cornification protein filaggrin underlie ichthyosis vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1429717" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Characterization of the human epidermal profilaggrin gene. Genomic organization and identification of an S-100-like calcium binding domain at the amino terminus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8417356" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Profilaggrin is a major epidermal calcium-binding protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/732879" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Assembly of stratum corneum basic protein and keratin filaments in macrofibrils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21991953" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Filaggrin mutations associated with skin and allergic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19681860" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Filaggrin haploinsufficiency is highly penetrant and is associated with increased severity of eczema: further delineation of the skin phenotype in a prospective epidemiological study of 792 school children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21428977" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Wide spectrum of filaggrin-null mutations in atopic dermatitis highlights differences between Singaporean Chinese and European populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22677890" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Topographic and biomechanical evaluation of cornea in patients with ichthyosis vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22158554" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : One remarkable molecule: filaggrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19501237" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19589816" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18774165" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Filaggrin in atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094728" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prevalent and low-frequency null mutations in the filaggrin gene are associated with early-onset and persistent atopic eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18396323" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Filaggrin mutations, atopic eczema, hay fever, and asthma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19733298" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18455261" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical detection of ichthyosis vulgaris in an atopic dermatitis clinic: implications for allergic respiratory disease and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21377035" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17657246" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Filaggrin mutations are genetic modifying factors exacerbating X-linked ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21945601" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Exacerbation of X-linked ichthyosis phenotype in a female by inheritance of filaggrin and steroid sulfatase mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30021537" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Exacerbation of ichthyosis vulgaris phenotype by co-inheritance of STS and FLG mutations in a Chinese family with ichthyosis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19785597" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Increased pachyonychia congenita severity in patients with concurrent keratin and filaggrin mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28730607" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Concurrent Chondrodysplasia Punctata Type 2 (Conradi-Hunermann-Happle Syndrome) and Ichthyosis Vulgaris in Teenaged Twin Girls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21326297" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Filaggrin null mutations are not a protective factor for acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17410197" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Filaggrin null alleles are not associated with psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17034559" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Filaggrin loss-of-function variant contributes to atopic dermatitis risk in the population of Northern Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19408338" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Filaggrin loss-of-function variants are associated with atopic comorbidity in pediatric inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4117150" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Ultrastructural distinction of autosomal dominant ichthyosis vulgaris and X-linked recessive ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12190941" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Absence of the granular layer and keratohyalin define a morphologically distinct subset of individuals with ichthyosis vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20080321" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : X-linked ichthyosis: an oculocutaneous genodermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17010746" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Acquired ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27913962" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Bathing and Associated Treatments in Atopic Dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20398816" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Scaly skin and bath pH: rediscovering baking soda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30216406" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Management of congenital ichthyoses: European guidelines of care, part one.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30681817" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Principles of Moisturizer Product Design</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26267423" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clinical Effectiveness of Moisturizers in Atopic Dermatitis and Related Disorders: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3543073" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Therapeutic activity of lactate 12% lotion in the treatment of ichthyosis. Active versus vehicle and active versus a petrolatum cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22007909" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Efficacy of topical 10% urea-based lotion in patients with ichthyosis vulgaris: a two-center, randomized, controlled, single-blind, right-vs.-left study in comparison with standard glycerol-based emollient cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30378232" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Topical urea in skincare: A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28432721" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Emollients and moisturizers for eczema: abridged Cochrane systematic review including GRADE assessments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25510955" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Burden of inherited ichthyosis: a French national survey.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
